These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


454 related items for PubMed ID: 23089183

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, Rambaldi A, Morello E, Narni F, Santarone S, Locatelli F, Bacigalupo A, Gruppo Italiano Trapianto Midollo Osseo (GITMO).
    Am J Hematol; 2007 Oct; 82(10):863-6. PubMed ID: 17616972
    [Abstract] [Full Text] [Related]

  • 23. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 26. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C, Perreau V, Bilger K, Coso D, Stoppa AM, Tabrizi R, Gastaut JA, Michallet M, Maraninchi D, Blaise D.
    Bone Marrow Transplant; 2004 Jul 15; 34(1):77-84. PubMed ID: 15133485
    [Abstract] [Full Text] [Related]

  • 27. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 15; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, García-Marco JA, Volin L, Schmitz N, Schwerdtfeger R, Ganser A, Onida F, Mohr B, Stilgenbauer S, Bornhäuser M, de Witte T, Dreger P.
    J Clin Oncol; 2008 Nov 01; 26(31):5094-100. PubMed ID: 18711173
    [Abstract] [Full Text] [Related]

  • 31. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianní L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S.
    Cancer; 2005 Dec 15; 104(12):2743-52. PubMed ID: 16284990
    [Abstract] [Full Text] [Related]

  • 32. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb 15; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

  • 33. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF.
    Biol Blood Marrow Transplant; 2008 Feb 15; 14(2):181-6. PubMed ID: 18215778
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
    Wäsch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R, Veelken H, Holler E, Finke J.
    Bone Marrow Transplant; 2000 Aug 15; 26(3):243-50. PubMed ID: 10967561
    [Abstract] [Full Text] [Related]

  • 36. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug 15; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 37. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G.
    Biol Blood Marrow Transplant; 2012 Mar 15; 18(3):466-72. PubMed ID: 21963618
    [Abstract] [Full Text] [Related]

  • 38. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, Szer J, Roberts AW, To LB, Kennedy G, Bradstock KF.
    Biol Blood Marrow Transplant; 2007 May 15; 13(5):560-7. PubMed ID: 17448915
    [Abstract] [Full Text] [Related]

  • 39. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bornhäuser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, Plettig R, Röllig C, Naumann R, Kroschinsky F, Neubauer A, Ehninger G.
    Bone Marrow Transplant; 2000 Jul 15; 26(2):119-25. PubMed ID: 10918420
    [Abstract] [Full Text] [Related]

  • 40. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
    Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G.
    Bone Marrow Transplant; 2009 Dec 15; 44(12):785-92. PubMed ID: 19430496
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 23.